

## **Elections to EACVI Board 2024-2026**



Application for the position: (Select one position)
☐ EACVI President-Elect
☐ EACVI Treasurer
☐ EACVI Secretary
☐ EACVI Councillor (Echocardiography)
☐ EACVI Councillor (Cardiovascular Magnetic Resonance)
☐ EACVI Councillor (Nuclear Cardiology & Cardiac CT)
☐ EACVI Vice-President-Elect (Echocardiography)
☐ EACVI Vice-President-Elect (Cardiovascular Magnetic Resonance)
☐ EACVI Vice-President-Elect (Nuclear Cardiology & Cardiac CT)
☑ EACVI Ordinary Nominating Committee member

1. Your Identity		
Title	Dr	
Family Name(s)	Wamil	
First Name(s)	Malgorzata	
Birth Date	22/02/1978	
Type of address	Business 🗵	Home $\square$
Institute/Organisation	Great Western Hospital I	NHS Trust
Department	Cardiology Department	
Address	Marlborough Road	
Post Code/Zip	SN3 6BB	
City	Swindon	
Country	UK	
Mobile Phone		



Phone	
Email	

## 2. Previous experience(s) in the EACVI or ESC or your National Bodies?

- 1) 2020-2024 European Association of Cardiovascular Imaging, Leaders of Tomorrow programme
- 2) 2019-present NICE Diabetes Pharma committee member/cardiology advisor
- 3) 2016-present Society of Cardiovascular Computed Tomography
- 4) 2014-present Society of Cardiovascular Magnetic Resonance, Member of the SCMR Clinical Trials Committee
- 5) 2011-present Royal Colleges of Physicians training board
- 6) 2010-present British Society of Echocardiography
- 7) 2005-present European Society of Cardiology (Fellow since 2022)
- 8) 2022- EACVI Industry Round Table Committee Member
- 9) British Society of Echocardiography Research and Audit Committee Member
- 10) ESC educational grant to complete MSc in Clinical Trials at the University of Oxford

3. Are you a Board or Nucleus Member of another scientific organisation?		
Yes □ No ⊠		
If Yes, please specify:		

4. Selected publications (please list 10 max)





- **1. Wamil M,** Hassaine A, Rao S, Li Y, Mamouei M, Canoy D, Nazarzadeh M, Bidel Z, Copland E, Rahimi K and Salimi-Khorshidi G, Stratification of diabetes in the context of comorbidities, using representation learning and topological data analysis; **Scientific Reports**, 2023 Jul16;13(1):11478
- **2. Wamil M**, Goncalves M, Rutherford A, Borlotti A, Pellikka PA, Multi-modality cardiac imaging in the management of diabetic heart disease **Frontiers of Cardiovascular Medicine** 2022 Nov 3:9:1043711
- 3. Rahimi K, Bidel Z, Nazarzadeh M, Coplan E, Canoy D, **Wamil M,** Majert J, McManus R; Agestratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis, **Lancet** 26 Aug 2021 S0140 6736(21)01921-8.
- 4. Dennis A, **Wamil M**, Alberts J, Oben J, Cuthbertson DJ, Wootton D, Crooks M, Gabbay M, Brady M, Hishmeh L, Attree E, Heightman M, Banerjee R, Banerjee A; COVERSCAN study investigators; Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study **BMJ Open** 2021 Mar 30;11(3): e 048391
- 5. Challa A, Negm A, Mahayni A, **Wamil M**, Williamson E, Guerrero M, Weishaar P, Collins J. Transcatheter Mitral Valve Replacement: Treatment Planning With Computed Tomography **Seminars Roent.** 2024 Jan;59(1):67-75
- **6. Wamil M**, Coleman R, Adler IA, McMurray J, Holman RR; Increased Risk of Incident Heart Failure and All-cause Mortality in People with Insulin Resistance in the United Kingdom Prospective Diabetes Study: UKPDS; <u>Diabetes Care</u> 2021 Aug;44(8):1877-1884
- **7. Wamil M**, McMurray JJ, Scott CAB, Coleman RL, Sun Y, Standl E, Rydén L, Holman RR Incidence, predictors, and importance of heart failure events in patients with impaired glucose tolerance in the Acarbose Cardiovascular Evaluation (ACE) trial, **Diabetes Research and Clinical Practice** 2020 Dec 170:108488
- 8. **Wamil M**, Borlotti A, Briosa e Gala A, Bracco A, Liu D, Piechnik S, Ferreira V, Alkalil M, DeMaria G, Fahrni G, Dawkins S, Wolfrum M, Banning A, Kharbanda R, Neubauer S, Choudhury R, Channon K, Dall'Armellina E Combined T1-mapping and tissue tracking analysis improves assessment of adverse LV remodeling following acute STEMI- an Oxford Acute Myocardial Infarction (OxAMI) study <u>International Journal of Cardiovascular Imaging</u> 2019 Jul, 5(7):1297-1308
- 9. **Wamil M**, Bull S and Newton J. The modern role of transoesophageal echocardiography in the management of valvular pathologies. **Echo Research and Practice** Jan 18





10. **Wamil M**, Battle JH, Turban S, Kipari T, Peixoto RS, Fernbach D, Ramage L, Chapman KE, Hughes J, Dunbar D, Seckl JR and Morton NM. Depot-specific insulin-sensitizion and reduced inflammation drives the protective fat distribution of  $11\beta$ -HSD1-/- mice. <u>Diabetes</u> 2011, Apr;60(4):1158-67.

## 5. Publication metrics

ORCID ID: 0000-0002-5361-2532

Google scholar profile link: https://scholar.google.com/citations?hl=en&user=Igj7wZYAAAAJ

Google scholar h-index: 17

## 6. Total number of peer reviewed publications / textbooks and chapters

Publications on Pubmed 25

In revision 5

Google scholar record: 41

Chapters 2

7. Why are you interested in joining the EACVI Board (300 words max)?





Joining the European Association of Cardiovascular Imaging Board presents an exciting opportunity to contribute to the advancement of cardiovascular imaging in Europe. My interest in this role is driven by a deep commitment to enhancing patient care through innovative imaging technologies and fostering the development of multi-modality cardiac imaging.

Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, and effective imaging is crucial for accurate diagnosis and management. Non-invasive, multimodality cardiac imaging offers a unique insight into cardiac anatomy, function, and perfusion, providing invaluable information that can significantly influence clinical decision-making. By serving on the EACVI Board, I aim to leverage my expertise in these modalities to advance the field and improve patient outcomes.

One of my primary motivations is to support and enhance the EACVI's mission of promoting excellence in cardiovascular imaging. This includes advocating for patient-cantered research that prioritises clinical benefits over technological advancements. By focusing on patient outcomes, we can ensure that our research efforts translate into tangible benefits for those we serve.

Interdisciplinary collaboration is another key driver of my interest. The integration of diverse imaging modalities, such as Cardiac CT, Cardiac MRI and echocardiography requires effective collaboration among various specialties. Serving on the EACVI Board would allow me to bridge the gap between different imaging disciplines, fostering a more cohesive and comprehensive approach to cardiovascular imaging.

Furthermore, I am passionate about education and professional development. I would work to develop robust certification and accreditation programs, ensuring that practitioners meet the highest standards of excellence. By promoting continuous learning and adherence to best practices, we can elevate the overall quality of cardiovascular imaging.

Lastly, my vision aligns with the EACVI's objective of organising impactful congresses and publishing high-quality research. I am eager to contribute to these efforts by spearheading initiatives that highlight the latest advancements in cardiac imaging, thereby driving innovation and setting new benchmarks in the field.

In summary, my interest in joining the EACVI stems from a dedication to improving patient care, fostering interdisciplinary collaboration, and promoting educational excellence. I am excited about the opportunity to contribute to the EACVI's mission and to help shape the future of cardiovascular imaging.

